Artelo Biosciences Q2 net loss narrows as R&D expenses fall
ARTL•Quarterly results
- Clinical-stage pharmaceutical firm's Q2 net loss narrowed yr/yr
- R&D expenses for Q2 decreased, while G&A expenses rose yr/yr
- Company completed $11.0 mln financing, strengthening balance sheet
| Metric | Beat/Miss | Actual | Consensus Estimate |
| Q2 Loss Per Share | $0.89 | ||
| Q2 Net Loss | $2.40 mln |
Outlook and development plans
-
Artelo plans to begin a Phase 1 multiple ascending dose study for ART26.12 in Q4 2026
-
Company expects to start human clinical studies for ART12.11 in the first half of 2026
-
Company is conducting a fully funded Phase 2 clinical study in glaucoma for ART27.13
-
LOWER R&D SPENDING - Co reported a decrease in research and development expenses for Q2 2026 compared to prior yr
